Entera Bio Ltd. (ENTX)

Several events have impacted Entera Bio Ltd.'s stock price over the past six months. The FDA's agreement on the EB613 Phase 3 study design, confirming Bone Mineral Density (BMD) as the primary endpoint, was a significant de-risking event. Positive Phase 2 data for EB613, demonstrating significant bone density improvements, led to a rise in the stock price. Positive pharmacokinetic (PK) data was reported for its first-in-class oral GLP-2 tablet treatment for patients with Short Bowel Syndrome. The company reported its Q3 2025 financial results, with an EPS of $(0.07), beating the $(0.09) estimate. The company reported its Q2 2025 financial results, with a net loss of $2.7 million, or $0.06 per ordinary share. The company reported its Q1 2025 financial results, with a net loss of $2.6 million, or $0.06 per ordinary share, and announced the extension of its cash runway into late 2026. The stock price as of November 21, 2025, was $2.53 per share, representing an increase of 51.50% from November 25, 2024, and has fluctuated between $1.50 and $3.22 over the past 52 weeks.

The provided information does not contain specific details about the demand seasonality for Entera Bio Ltd.'s products and services. Its revenue generation is primarily tied to research and development milestones, partnerships, and potential future drug approvals, rather than seasonal consumer demand.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing oral peptide and protein replacement therapies using its proprietary N-Tab™ oral drug delivery platform. Its lead product, EB613, is being developed as an oral treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis and is preparing for Phase 3 trials. Other pipeline candidates include EB612 for hypoparathyroidism, oral Oxyntomodulin for obesity and metabolic syndromes (co-developed with OPKO Health), and an oral GLP-2 peptide tablet for rare malabsorption conditions.

Entera Bio Ltd. is headquartered in Jerusalem, Israel, where its research and development operations are centered. The company's shares are listed on the Nasdaq Capital Market in the US and on the Deutsche Boerse AG in Germany.

Entera Bio's brand reputation has been positively influenced by its clinical advancements and strategic partnerships. The FDA's agreement on the Phase 3 study design for EB613 is a significant validation. Presentation of positive Phase 2 data for EB613 and positive PK data for the oral GLP-2 tablet at major medical conferences has bolstered its scientific credibility. The co-development of the oral Oxyntomodulin (OXM) program with OPKO Health demonstrates external validation. The company's ability to extend its cash runway into late 2026 indicates financial stability and investor confidence. No significant negative events impacting brand reputation were found.

Entera Bio Ltd.'s ownership structure shows a significant concentration of shares in the hands of the general public, holding a substantial 55% stake. Knoll Capital Management, LLC is the largest single shareholder, holding 13% of shares as of October 2025. Other major institutional owners include Point72 Asset Management, L.P., Marshall Wace, Llp, Schonfeld Strategic Advisors LLC, Parkman Healthcare Partners LLC, Northern Trust Corp, Bessemer Group Inc, Renaissance Technologies Llc, Susquehanna International Group, Llp, Signature Estate & Investment Advisors Llc, and OPKO Health, Inc., which owns 8.1% of shares outstanding as of October 2025. Company insiders also own some shares.